Eli Lilly (LLY) is a publicly traded Healthcare sector company. As of May 20, 2026, LLY trades at $1,017.13 with a market cap of $881.12B and a P/E ratio of 43.77. LLY moved -0.53% today. Year to date, LLY is -5.46%; over the trailing twelve months it is +35.27%. Its 52-week range spans $623.78 to $1,133.95. Analyst consensus is strong buy with an average price target of $1,262.85. Rallies surfaces LLY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Eli Lilly Sues Church Leaders Over $200M Trulicity Rebate Fraud: Eli Lilly filed a civil lawsuit in federal court alleging a rebate fraud scheme cost the company over $200 million. The suit claims bishops and a leader of the Church of God in Christ orchestrated the scheme by submitting fraudulent Trulicity drug rebate claims.
| Metric | Value |
|---|---|
| Price | $1,017.13 |
| Market Cap | $881.12B |
| P/E Ratio | 43.77 |
| EPS | $23.00 |
| Dividend Yield | 1.73% |
| 52-Week High | $1,133.95 |
| 52-Week Low | $623.78 |
| Volume | 2.02M |
| Avg Volume | 0 |
| Revenue (TTM) | $65.18B |
| Net Income | $20.64B |
| Gross Margin | 83.04% |
22 analysts cover LLY: 0 strong buy, 19 buy, 2 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $1,262.85.